SCHEMBL31069299

SCHEMBL31069299

NCc1ccc2c(c1)cc(Cn1c(=O)n(C3CC3)c3ccc(F)cc31)n2CC1CCC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
NPSR1 Q6W5P4 2/20 0.38
TSHR P16473 1/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
OPRM1 P35372 3/20 0.35
OPRL1 P41146 2/20 0.34
OPRK1 P41145 1/20 0.34
CACNA1G O43497 2/20 0.33
CACNA1H O95180 2/20 0.33
MAPK9 P45984 1/20 0.33
GRIA2 P42262 1/20 0.32
GRIN2A Q12879 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31069305 0.88 CYP3A4 (0.41) CYP3A4NPSR1TSHRCRHBPCRHR2
SCHEMBL31069388 0.88 PARG (0.38) CYP3A4NPSR1OPRM1OPRL1OPRK1
SCHEMBL31069408 0.87 CYP3A4 (0.38) CYP3A4NPSR1TSHRCRHBPCRHR2
SCHEMBL31069322 0.86 CACNA1G (0.40) CYP3A4NPSR1TSHRCRHBPCRHR2
SCHEMBL31069312 0.85 CYP3A4 (0.32) CYP3A4MAPK9GRIA2GRIN2A
SCHEMBL31069404 0.84 CYP3A4 (0.48) CYP3A4NPSR1TSHRCRHBPCRHR2
SCHEMBL31069245 0.82 CYP3A4 (0.38) CYP3A4NPSR1ALDH1A1POLBCACNA1G
SCHEMBL31069413 0.76 CYP3A4 (0.43) CYP3A4CACNA1GCACNA1H
SCHEMBL31069366 0.76 PARG (0.36)
SCHEMBL31069389 0.72 PARG (0.36) TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024174953-A1 BENZIMIDAZOLE DERIVATIVE AND MEDICAL USE THEREOF 苏州隆博泰药业有限公司 2024-08-29 WO claimed
WO-2024174953-A1 BENZIMIDAZOLE DERIVATIVE AND MEDICAL USE THEREOF 苏州隆博泰药业有限公司 2024-08-29 WO disclosed